Sort   by:  
 Page size 
UnknownThe Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19.

Background

Levels of plasma SARS-CoV-2 nucleocapsid (N) antigen may be an important biomarker in patients with COVID-19 and enhance our understanding of the pathogenesis of COVID-19.

Objective

To evaluate whether levels of plasma antigen can predict short-term clinical outcomes and id...
S-EPMC9447373 | biostudies-literature
UnknownWhole-Body Hypothermia for Neonatal Encephalopathy in Preterm Infants 33 to 35 Weeks' Gestation: A Randomized Clinical Trial.

Importance

Hypothermia begun less than 6 hours after birth reduces death or disability in infants with encephalopathy due to hypoxia-ischemia at 36 or more weeks' gestation. Trials of hypothermia for infants younger than 36 weeks' gestation are lacking.

Objective

To assess the probabi...
S-EPMC11851295 | biostudies-literature
UnknownResearching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design.

Importance

SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or other health effects after the acute phase of infection; termed post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC are ill-d...
S-EPMC10289397 | biostudies-literature
UnknownEfficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.

Background

Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection.

Objective

To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes am...
S-EPMC9384272 | biostudies-literature
UnknownEarly trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study.

Background

Serial measurement of virological and immunological biomarkers in patients admitted to hospital with COVID-19 can give valuable insight into the pathogenic roles of viral replication and immune dysregulation. We aimed to characterise biomarker trajectories and their associations w...
S-EPMC11181148 | biostudies-literature
UnknownMeasurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study.

Objectives

To determine the proportion of individuals with detectable antigen in plasma or serum after SARS-CoV-2 infection and the association of antigen detection with postacute sequelae of COVID-19 (PASC) symptoms.

Methods

Plasma and serum samples were collected from adults partici...
S-EPMC11578795 | biostudies-literature
UnknownOlfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort.

Importance

Olfactory dysfunction is common after SARS-CoV-2 infection and has been associated with cognitive loss in other conditions. Formal testing is needed to characterize the presence, severity, and patterns of olfactory dysfunction.

Objective

To characterize long-term olfactory ...
S-EPMC12464792 | biostudies-literature
UnknownLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Background

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

Methods

In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk t...
S-EPMC4985288 | biostudies-literature
UnknownHigher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

Background

Low dose corticosteroids (e.g., 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with clinical hypoxia but not receiving ventilatory support (the combination o...
S-EPMC11872607 | biostudies-literature
UnknownEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Background

Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.

Methods

In the randomised, cont...
S-EPMC10957483 | biostudies-literature
Sort   by:  
 Page size